Biotech News

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus (ABUS)Arbutus2026-06-25 13:46 ESTConference / presentation

Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including

Open original release

Related news

ABUSArbutus2026-06-25 13:46 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-25 13:46 EST

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

ABUSArbutus2026-06-25 13:46 EST

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-25 13:46 EST

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

ABUSArbutus2026-06-25 13:46 EST

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-25 13:46 EST

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

ABUSArbutus2026-06-25 13:46 EST

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-25 13:46 EST

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

ABUSArbutus2026-06-25 13:46 EST

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-25 13:46 EST

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

View all latest news

Arbutus

Arbutus is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ABUSArbutus2026-06-26 09:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-26 09:30 EST

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

ABUSArbutus2026-06-26 09:30 EST

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

ABUSArbutus2026-06-26 09:30 EST

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-26 09:30 EST

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States